The Rundown: ExL’s Blog
Viewing 11 to 20 of 31 records.
An Insider’s Look at Results: The Future of Pharmaceutical and Healthcare Marketing
Wednesday October 21st, 2015
The changing nature of the relationship between life science companies and their clients is a hot topic that comes up at our events. We recently had the pleasure of reading Results: The Future of Pharmaceutical and Healthcare Marketing, a new book about the top trends shaping how healthcare and pharma companies approach marketing in today’s rapidly evolving world, and jumped at the opportunity to interview its authors. Here’s what they had to say in response to our questions.
What were the primary catalysts that spurred you to write Results?
Is Your Competitive Intelligence Saving You Money?
Thursday October 15th, 2015
In 2014, global pharmaceutical sales amounted to almost 1 trillion dollars worldwide. The life science industry is huge, and it is growing each year, but the competition is getting fierce.
Gathering and utilizing competitive information to improve your organization’s bottom line can be a tricky process. Big data is getting more overwhelming each day, but transferring that information mass into valuable insights can spark more strategic outreach and help skyrocket company ROI. Indeed, Sanofi’s head of US regulatory policy and intelligence, Linda Bowen, recently
Abuse-Deterrent Formulations Save Lives
Thursday October 1st, 2015
This guest blog post is written by Dan Cohen. Dan is the Forum Chair of the Abuse Deterrent Coalition. For more information, go to www.abusedeterrent.org.
As we near the end of 2015, it is obvious that the prescription drug crisis identified by the White House in 2011 has gotten even more desperate and requires urgent action. An estimated 16,000 lives are lost each year due to prescription opioid abuse. That’s 46 mothers, fathers, sisters and brothers lost every single day of the year.
Prescription drug abuse is…
Media Roundup — Coverage from 5th Digital Marketing for Medical Devices
Friday September 18th, 2015
With more than 140 industry marketers, sales professionals and thought leaders in attendance at the 5th Digital Marketing for Medical Devices conference, this three-day event was a resounding success. The speakers were insightful and engaging, and delegates returned to work armed with best practices and new strategies to try in their workplaces — but don’t just take our word for it. These recaps will give you a glimpse of what you may have missed if you were unable to come to this event.
Words of Wisdom from Prolifiq and App Data…
Patient Medication Adherence Should Be a Priority in Our Healthcare System
Saturday September 12th, 2015
We live in a time when patients have more control over what kind of medications they take and how they take them. Though there are many positives associated with this freedom and the opportunities it presents, patient adherence has become a growing problem in our healthcare system. Many people fail to realize what can happen when individuals do not practice patient adherence, especially when it comes to taking their medication.
A CapGemini report estimates that the cost of poor medication adherence in the United States is as much as
Peter Shankman and Pharma Experts Weigh In: How “Niceness” Can Help Your Brand
Thursday September 3rd, 2015
This guest blog post is written by Dave Hochman. Dave is the owner of the Red Bank, NJ-based DJH Marketing Communications, Inc. For more information, go to www.djhmarcom.com, email email@example.com or follow Dave on Twitter @davehochman.
One of the first day’s speakers at Exl Pharma’s 11th Public Relations & Communications Summit at Sanofi US in July was Peter Shankman, a PR industry pundit and the author of such books as “Zombie Loyalists: Using Great Service to Create…
An Interview with Atul Mahableshwarkar, CNS Clinical Trial Forum Chair
Friday August 28th, 2015
|Conference chair Atul Mahableshwarkar, M.D., DFAPA|
CNS clinical trials are some of the most intricate, time-consuming processes modern life science professionals deal with. They necessitate a great deal of attention to detail and a strong commitment to quality from all involved parties. With ExL Events’ premiere CNS Clinical Trial Forum rapidly approaching, we spoke to conference chairperson Atul R. Mahableshwarkar, M.D., DFAPA, to learn more about him and his thoughts on this timely topic.
How did you become involved in…
The Value of Healthcare: Examining the Rising Cost of Prescription Drugs
Sunday August 23rd, 2015
Healthcare reform has been a major topic in America the last few years. Everyone wants to see the cost of staying healthy go down, or at least become affordable. The problem is those costs consist of several different factors. Getting control of expenses becomes difficult when one factor’s price rises. Such is the case with the increasing costs of prescription drugs.
Rising costs imperil the goal of maintaining good health and create the potential for greater costs in the long run. The obstacles presented by the inability…
Colleagues, Coffee and Communications — A Roundup of the #ExLPRSummit Coverage
Thursday August 13th, 2015
When the 11th Annual Public Relations & Communications Summit took place in July, more than 150 PR and comm professionals joined ExL Pharma at Sanofi’s New Jersey headquarters to participate in one of our favorite conferences of the year. We love engaging with our audience and hearing their thoughts, and are excited to share coverage of the event through their eyes with you.
What Attendees Had to Say
On the Makovsky Health blog, Group Vice President Rob Murphy discussed the importance of meaningful connections and value-added interactions….
A Groundbreaking Study in Latin America
Tuesday August 4th, 2015
Located in the northern hills of the Latin American country of Columbia, the secluded towns in the state of Antioquia give scientists a unique opportunity to study disease. As a result of its long-term isolation from newcomers, the intermarriage of residents has allowed genetic mutations to persist through generations.
Because the region’s gene pool has not experienced any significant genetic mingling, it is ideal for studying bipolar and cardiovascular disease, Alzheimer’s disease, and juvenile diabetes. Unlike general population studies requiring big data collection to tease out disease…